Impact factors


Clinical Projects

Publication Highlights

  1. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLOS Medicine. 2021 August 31; doi:10.1371/journal.pmed.1003741

  2. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology. 2021 May 17; 14, 80. doi:10.1186/s13045-021-01089-z
  3. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical Cancer Research. 2020 Dec 1;26(23):6168-6175. doi: 10.1158/1078-0432.CCR-20-2081.
  4. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.
  5. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC. Journal of Thoracic Oncology. 2019 Dec;14(12):e263-e266. doi: 10.1016/j.jtho.2019.07.012.
  6. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer. Clinical Cancer Research. 2019 Aug 15;25(16):5015-5026. doi: 10.1158/1078-0432.CCR-19-0585.
  7. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019 Jul 28;9(19):5532-5541. doi: 10.7150/thno.34070.
  8. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters. 2020 Mar 1;472:108-118. doi: 10.1016/j.canlet.2019.12.004.
  9. Timing and Origins of Local and Distant Metastases in Lung Cancer. Journal of Thoracic Oncology. 2021 Mar 12. doi:10.1016/j.jtho.2021.02.023
  10. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019 Jul;68(7):1152-1161. doi: 10.1136/gutjnl-2018-316522.
  11. EGFR and ERBB2 Germline Mutations in Chinese Lung cancer Patients and Their Roles in Genetic Susceptibility to Cancer. Journal of Thoracic Oncology. 2019 Apr;14(4):732-736. doi: 10.1016/j.jtho.2018.12.006.
  12. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019 Jan 1;142(1):23-34. doi: 10.1093/brain/awy307.
  13. Clinical And Molecular Features Of Acute Promyelocytic Leukemia With Variant Retinoid Acid Receptor Fusions. Haematologica. 2019 May;104(5):e195-e199. doi: 10.3324/haematol.2018.205369.
  14. Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. Clinical Cancer Research. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310.
  15. Circulating Tumor DNA Mutational Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. Scientific Reports. 2017 Apr 3;7(1):583. doi: 10.1038/s41598-017-00520-1.
  16. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. Journal of Thoracic Oncology. 2016 Sep;11(9):1503-10. doi: 10.1016/j.jtho.2016.05.016.